Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exforge Money-back Guarantee Leaves DDMAC Complaining

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis sales aid touting money-back guarantee on its blood pressure product implies the drug is more effective than competitors with no head-to-head evidence, FDA maintains.

You may also be interested in...



Novartis Advertising Cited By FDA For Fifth Time In Less Than A Year

CBER's Advertising and Promotional Labeling Branch says that Novartis improperly expanded the age range for its Fluvirin influenza vaccine.

Novartis Advertising Cited By FDA For Fifth Time In Less Than A Year

CBER's Advertising and Promotional Labeling Branch says that Novartis improperly expanded the age range for its Fluvirin influenza vaccine.

Novartis Makes Splash With Hypertension Disease Awareness Program

D.C. press conference to announce “money back guarantee” hypertension treatment program includes HHS Secretary Thompson. Novartis will launch hypertension disease awareness ads in May.

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel